Results 71 to 80 of about 3,528 (147)

Cellular Immune Response Induced by mRNA Vaccines Against SARS‐CoV‐2

Immunity, Inflammation and Disease, Volume 14, Issue 3, March 2026.
SARS‐CoV‐2 vaccine induces cellular immune response. T‐cells play a protective role for COVID‐19. ABSTRACT The disease caused by SARS‐CoV‐2 is known as COVID‐19, and it can range from mild symptoms to severe clinical manifestations, including respiratory failure, pneumonia, and organ failure. Since its emergence in 2019, more than 7 million deaths have
Valentina Tovar, Isaura Pilar Sánchez, María Teresa Rugeles, Natalia Andrea Taborda, Juan C. Hernandez   +4 more
wiley   +1 more source

Third COVID-19 vaccine dose for people with multiple sclerosis who did not seroconvert following two doses of BBIBP-CorV (Sinopharm) inactivated vaccine: A pilot study on safety and immunogenicity

Frontiers in Immunology, 2023
BackgroundPeople with multiple sclerosis (pwMS) on anti-CD20 therapies (aCD20) and fingolimod have shown inadequate humoral responses to COVID-19 vaccines.ObjectiveThe objective of the study was to pilot larger studies by demonstrating the safety and ...
Nahad Sedaghat, Nahad Sedaghat, Masoud Etemadifar, Noushin Lotfi, Farnaz Sayahi, Ahmad Chitsaz, Mehri Salari, Alireza Ghasemi Movaghar   +7 more
doaj   +1 more source

Complement Hyperactivation Is Mediated by Alternative and Lectin Pathways During Early Phase of Severe Vaccination‐Omicron BA.5 Infection

Journal of Medical Virology, Volume 98, Issue 3, March 2026.
ABSTRACT Complement temporal activation kinetics, activation pathways, and their relationship with thromboinflammation and antibody responses in severe vaccination‐COVID‐19 remains unclear. Based on a vaccinated‐infected cohort, we analyzed complement immune responses across mild to critical COVID‐19 cases by a dynamic model.
Jinpeng Cao, Gang Yang, Tingting Cui, Jian Qin, Deyi Huang, Shiqin Jin, Xiaoyun Yang, Mingzhu Huang, Xiaoling Su, Siyi Liu, Yingjiao Xia, Shidong Deng, Chengna Luo, Zhuxiang Zhao, Yunhui Zhang, Nanshan Zhong, Zhongfang Wang   +16 more
wiley   +1 more source

Data_Sheet_1_The BBIBP-CorV inactivated COVID-19 vaccine induces robust and persistent humoral responses to SARS-CoV-2 nucleocapsid, besides spike protein in healthy adults.docx

, 2022
Vaccination is one of the best ways to control the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic. Among the various SARS-CoV-2 vaccines approved for use, the BBIBP-CorV inactivated vaccine has been widely used in 93 countries.
Bin Li (39349), Ying Chen (9697), Chao Wu (199897), Taojun He (12006425), Fang Zhang (197215), Aixia Zhai (500106), Liang Shi (8078), Qinjin Wang (13951623), Jie Ning (3420689), Xingchi Chen (6090260)   +9 more
core   +1 more source

Immunologic assessment of the impact of SARS-CoV-2 vaccine booster doses on humoral immunity: a cross-sectional study in morocco

BMC Infectious Diseases
To assess the impact of the SARS-CoV-2 booster dose on the immune response against COVID-19, we conducted a cross-sectional study in the Casablanca-Settat region of Morocco.
Karima Abounouh, Raji Tajudeen, Hind Majidi, Soad Redwane, Oumaima Laazaazia, Safaa Aqillouch, Ahmed E. Ogwell Ouma, Mohammed Abdulaziz, Merawi Aragaw, Mosoka Papa Fallah, Senga Sembuche, Serge Batcho, Patrick Kabwe, Elizabeth Gonese, Abdelhakim Ainahi, M’hammed Sarih, Jean Kaseya, Abderrahmane Maaroufi, Sayeh Ezzikouri   +18 more
doaj   +1 more source

Neutralizing antibody geometric mean titer (GMT), mean rise, fold rise, and fourfold rise rate between ChAdOx1-S and BBIBP-CorV homologous and heterologous groups.

, 2023
Neutralizing antibody geometric mean titer (GMT), mean rise, fold rise, and fourfold rise rate between ChAdOx1-S and BBIBP-CorV homologous and heterologous groups.
Carmen Valenzuela Silva (17319206), Amitis Ramezani (6329339), Alireza Biglari (12152590), Sana Eybpoosh (2826068), Anahita Bavand (6329345), Mostafa Salehi-Vaziri (6273803), Mohammad Banifazl (17319212), Sarah Dahmardeh (17319209), Vicente Verez-Bencomo (17319200), Rahim Sorouri (17319194), Maria Eugenia Toledo-Romani (17319203), Ehsan Mostafavi (406077), Mona Sadat Larijani (17319197), Delaram Doroud (348344), Fatemeh Ashrafian (9619876)   +14 more
core   +1 more source

Safety and immunogenicity of COVID-19 BBIBP-CorV vaccine in children 3-12 years old

, 2022
Background and objectives: In the current COVID-19 pandemic, children below the age of 12 could manifest COVID-19 symptoms and serve as a reservoir for the virus in the community.
Ejlal Alalawi (12454820), Basma Alsaffar (12454817), Adel Alsayyad (12454822), Manaf AlQahtani (12596962), Abdulla Alawadhi (11796528), Amer Almarabheh (11174109), Ahmed Humaidan (12454829), Afaf Merza (12454823), Batool Alalawi (12059568), Khaled Greish (838539), Marwa AlMadhi (9945632), Ahmed Jaradat (12454813), Jaleela Jawad (12454816), Donia Qayed (12454826)   +13 more
core   +1 more source

Data_Sheet_1_Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2.docx

, 2023
BackgroundVaccination has proven the potential to control the COVID-19 pandemic worldwide. Although recent evidence suggests a poor humoral response against SARS-CoV-2 in vaccinated hematological disease (HD) patients, data on vaccination in these ...
Enikő Szabó (148916), Szabolcs Modok (2469526), Anna Faragó (16554870), László Hackler (16554873), Patrícia Neuperger (12324584), Nikolett Gémes (11659288), Lajos I. Nagy (5118512), Benedek Rónaszéki (16554867), László G. Puskás (6956558), Gabor J. Szebeni (15407471), József Á. Balog (12324587), Attila Balog (609909), Katalin Farkas (3453959)   +12 more
core   +1 more source

Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older

Expert Review of Vaccines, 2023
Background Because SARS-CoV-2 mutations and immunity wane over time, a third dose of heterologous COVID-19 vaccine is proposed for individuals primed with inactivated COVID-19 vaccine.
Yingping Chen, Xinpei Zhang, Lihui Gong, Zhenzhen Liang, Xiaosong Hu, Bo Xing, Yuting Liao, Lingfeng Yuan, Gang Chen, Huakun Lv   +9 more
doaj   +1 more source

The relationship between vaccination and uveitis: A comprehensive review of immune response, risk assessment, and clinical implications

Eye &ENT Research, Volume 2, Issue 1, Page 5-17, March 2025.
The review illustrates the possible immune responses provoked by diverse vaccines, encompassing the hepatitis B virus vaccine, human papillomavirus vaccine, measles‐mumps‐rubella combined vaccine, COVID‐19 vaccine and hepatitis A vaccine. These reponses span activation of the immune system, hypersensitivity reactions, molecular mimicry, and the role of
Yihan Zhang, Tianyu Tao, Zhaohuai Li, He Li, Qi Jiang, Lei Zhu, Wenru Su   +6 more
wiley   +1 more source